Postmenopausal vaginal atrophy (PVA) is the type of condition of vaginal wall thinning the reduced level of estrogen causes that. The changes in the genitourinary tract arising from a hypoestrogenic state includes decreased vaginal vascularization, reduced vaginal lubrication, thinning of the vaginal epithelium. The pH level continuously increases and loss of lactobacilli microflora allows opportunistic colonization by pathogenic bacteria can produce infection.

The global Postmenopausal Vaginal Atrophy Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Postmenopausal Vaginal Atrophy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Postmenopausal Vaginal Atrophy Drugs.

Report Scope

The Postmenopausal Vaginal Atrophy Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Postmenopausal Vaginal Atrophy Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Postmenopausal Vaginal Atrophy Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Postmenopausal Vaginal Atrophy Drugs Market Report

Report Metric	Details
Report Name	Postmenopausal Vaginal Atrophy Drugs Market
CAGR	5%
Segment by Type	Topical Estrogen Oral Estrogen Other
Segment by Application	Online Pharmacy Hospital Pharmacy
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Pfizer Inc, Mylan NV, Novartis AG, Hikma Pharmaceuticals plc, Aurobindo Pharma, AbbVie Inc, Melinta Therapeutics, Inc, Bristol-Myers Squibb Company, GSK plc, Bayer AG, Lupin, Perrigo Company plc, Bionovo, Inc, TherapeuticsMD, Inc, Endoceutics, Inc
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Postmenopausal Vaginal Atrophy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Postmenopausal Vaginal Atrophy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Postmenopausal Vaginal Atrophy Drugs Market report?

Ans: The main players in the Postmenopausal Vaginal Atrophy Drugs Market are Pfizer Inc, Mylan NV, Novartis AG, Hikma Pharmaceuticals plc, Aurobindo Pharma, AbbVie Inc, Melinta Therapeutics, Inc, Bristol-Myers Squibb Company, GSK plc, Bayer AG, Lupin, Perrigo Company plc, Bionovo, Inc, TherapeuticsMD, Inc, Endoceutics, Inc

What are the Application segmentation covered in the Postmenopausal Vaginal Atrophy Drugs Market report?

Ans: The Applications covered in the Postmenopausal Vaginal Atrophy Drugs Market report are Online Pharmacy, Hospital Pharmacy

What are the Type segmentation covered in the Postmenopausal Vaginal Atrophy Drugs Market report?

Ans: The Types covered in the Postmenopausal Vaginal Atrophy Drugs Market report are Topical Estrogen, Oral Estrogen, Other

1 Postmenopausal Vaginal Atrophy Drugs Market Overview

1.1 Product Overview and Scope of Postmenopausal Vaginal Atrophy Drugs

1.2 Postmenopausal Vaginal Atrophy Drugs Segment by Type

1.2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Value Comparison by Type (2024-2030)

1.2.2 Topical Estrogen

1.2.3 Oral Estrogen

1.2.4 Other

1.3 Postmenopausal Vaginal Atrophy Drugs Segment by Application

1.3.1 Global Postmenopausal Vaginal Atrophy Drugs Market Value by Application: (2024-2030)

1.3.2 Online Pharmacy

1.3.3 Hospital Pharmacy

1.4 Global Postmenopausal Vaginal Atrophy Drugs Market Size Estimates and Forecasts

1.4.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue 2019-2030

1.4.2 Global Postmenopausal Vaginal Atrophy Drugs Sales 2019-2030

1.4.3 Global Postmenopausal Vaginal Atrophy Drugs Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Postmenopausal Vaginal Atrophy Drugs Market Competition by Manufacturers

2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers (2019-2024)

2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Manufacturers (2019-2024)

2.4 Global Postmenopausal Vaginal Atrophy Drugs Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Postmenopausal Vaginal Atrophy Drugs, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Postmenopausal Vaginal Atrophy Drugs, Product Type & Application

2.7 Postmenopausal Vaginal Atrophy Drugs Market Competitive Situation and Trends

2.7.1 Postmenopausal Vaginal Atrophy Drugs Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Postmenopausal Vaginal Atrophy Drugs Players Market Share by Revenue

2.7.3 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario by Region

3.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Postmenopausal Vaginal Atrophy Drugs Global Postmenopausal Vaginal Atrophy Drugs Sales by Region: 2019-2030

3.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Region: 2019-2024

3.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Region: 2025-2030

3.3 Global Postmenopausal Vaginal Atrophy Drugs Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region: 2019-2030

3.3.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region: 2019-2024

3.3.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region: 2025-2030

3.4 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country

3.4.1 North America Postmenopausal Vaginal Atrophy Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2019-2030)

3.4.3 North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country

3.5.1 Europe Postmenopausal Vaginal Atrophy Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2019-2030)

3.5.3 Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country

3.6.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Country (2019-2030)

3.6.3 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country

3.7.1 Latin America Postmenopausal Vaginal Atrophy Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2019-2030)

3.7.3 Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2019-2030)

3.8.3 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2019-2030)

4.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2019-2024)

4.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2025-2030)

4.1.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2019-2030)

4.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2019-2030)

4.2.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2019-2024)

4.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2025-2030)

4.2.3 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2019-2030)

4.3 Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2019-2030)

5 Segment by Application

5.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2019-2030)

5.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2019-2024)

5.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2025-2030)

5.1.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2019-2030)

5.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2019-2030)

5.2.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2019-2024)

5.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2025-2030)

5.2.3 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2019-2030)

5.3 Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Pfizer Inc

6.1.1 Pfizer Inc Corporation Information

6.1.2 Pfizer Inc Description and Business Overview

6.1.3 Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Product Portfolio

6.1.5 Pfizer Inc Recent Developments/Updates

6.2 Mylan NV

6.2.1 Mylan NV Corporation Information

6.2.2 Mylan NV Description and Business Overview

6.2.3 Mylan NV Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Mylan NV Postmenopausal Vaginal Atrophy Drugs Product Portfolio

6.2.5 Mylan NV Recent Developments/Updates

6.3 Novartis AG

6.3.1 Novartis AG Corporation Information

6.3.2 Novartis AG Description and Business Overview

6.3.3 Novartis AG Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Novartis AG Postmenopausal Vaginal Atrophy Drugs Product Portfolio

6.3.5 Novartis AG Recent Developments/Updates

6.4 Hikma Pharmaceuticals plc

6.4.1 Hikma Pharmaceuticals plc Corporation Information

6.4.2 Hikma Pharmaceuticals plc Description and Business Overview

6.4.3 Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Product Portfolio

6.4.5 Hikma Pharmaceuticals plc Recent Developments/Updates

6.5 Aurobindo Pharma

6.5.1 Aurobindo Pharma Corporation Information

6.5.2 Aurobindo Pharma Description and Business Overview

6.5.3 Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Product Portfolio

6.5.5 Aurobindo Pharma Recent Developments/Updates

6.6 AbbVie Inc

6.6.1 AbbVie Inc Corporation Information

6.6.2 AbbVie Inc Description and Business Overview

6.6.3 AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.6.4 AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Product Portfolio

6.6.5 AbbVie Inc Recent Developments/Updates

6.7 Melinta Therapeutics, Inc

6.6.1 Melinta Therapeutics, Inc Corporation Information

6.6.2 Melinta Therapeutics, Inc Description and Business Overview

6.6.3 Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Product Portfolio

6.7.5 Melinta Therapeutics, Inc Recent Developments/Updates

6.8 Bristol-Myers Squibb Company

6.8.1 Bristol-Myers Squibb Company Corporation Information

6.8.2 Bristol-Myers Squibb Company Description and Business Overview

6.8.3 Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Product Portfolio

6.8.5 Bristol-Myers Squibb Company Recent Developments/Updates

6.9 GSK plc

6.9.1 GSK plc Corporation Information

6.9.2 GSK plc Description and Business Overview

6.9.3 GSK plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.9.4 GSK plc Postmenopausal Vaginal Atrophy Drugs Product Portfolio

6.9.5 GSK plc Recent Developments/Updates

6.10 Bayer AG

6.10.1 Bayer AG Corporation Information

6.10.2 Bayer AG Description and Business Overview

6.10.3 Bayer AG Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Bayer AG Postmenopausal Vaginal Atrophy Drugs Product Portfolio

6.10.5 Bayer AG Recent Developments/Updates

6.11 Lupin

6.11.1 Lupin Corporation Information

6.11.2 Lupin Postmenopausal Vaginal Atrophy Drugs Description and Business Overview

6.11.3 Lupin Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.11.4 Lupin Postmenopausal Vaginal Atrophy Drugs Product Portfolio

6.11.5 Lupin Recent Developments/Updates

6.12 Perrigo Company plc

6.12.1 Perrigo Company plc Corporation Information

6.12.2 Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Description and Business Overview

6.12.3 Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Product Portfolio

6.12.5 Perrigo Company plc Recent Developments/Updates

6.13 Bionovo, Inc

6.13.1 Bionovo, Inc Corporation Information

6.13.2 Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Description and Business Overview

6.13.3 Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.13.4 Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Product Portfolio

6.13.5 Bionovo, Inc Recent Developments/Updates

6.14 TherapeuticsMD, Inc

6.14.1 TherapeuticsMD, Inc Corporation Information

6.14.2 TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Description and Business Overview

6.14.3 TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.14.4 TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Product Portfolio

6.14.5 TherapeuticsMD, Inc Recent Developments/Updates

6.15 Endoceutics, Inc

6.15.1 Endoceutics, Inc Corporation Information

6.15.2 Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Description and Business Overview

6.15.3 Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2019-2024)

6.15.4 Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Product Portfolio

6.15.5 Endoceutics, Inc Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Postmenopausal Vaginal Atrophy Drugs Industry Chain Analysis

7.2 Postmenopausal Vaginal Atrophy Drugs Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Postmenopausal Vaginal Atrophy Drugs Production Mode & Process

7.4 Postmenopausal Vaginal Atrophy Drugs Sales and Marketing

7.4.1 Postmenopausal Vaginal Atrophy Drugs Sales Channels

7.4.2 Postmenopausal Vaginal Atrophy Drugs Distributors

7.5 Postmenopausal Vaginal Atrophy Drugs Customers

8 Postmenopausal Vaginal Atrophy Drugs Market Dynamics

8.1 Postmenopausal Vaginal Atrophy Drugs Industry Trends

8.2 Postmenopausal Vaginal Atrophy Drugs Market Drivers

8.3 Postmenopausal Vaginal Atrophy Drugs Market Challenges

8.4 Postmenopausal Vaginal Atrophy Drugs Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Hikma Pharmaceuticals PLC

Aurobindo Pharma

AbbVie

Melinta Therapeutics Inc

Bristol Myers Squibb Company

List of Tables

Table 1. Global Postmenopausal Vaginal Atrophy Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Postmenopausal Vaginal Atrophy Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Postmenopausal Vaginal Atrophy Drugs Market Competitive Situation by Manufacturers in 2023

Table 4. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Postmenopausal Vaginal Atrophy Drugs Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Postmenopausal Vaginal Atrophy Drugs, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Postmenopausal Vaginal Atrophy Drugs, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Postmenopausal Vaginal Atrophy Drugs, Product Type & Application

Table 12. Global Key Manufacturers of Postmenopausal Vaginal Atrophy Drugs, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Postmenopausal Vaginal Atrophy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Postmenopausal Vaginal Atrophy Drugs as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2019-2024) & (K Units)

Table 18. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2019-2024)

Table 19. Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2025-2030) & (K Units)

Table 20. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2025-2030)

Table 21. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2019-2024)

Table 23. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2025-2030)

Table 25. North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2019-2024) & (K Units)

Table 27. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2025-2030) & (K Units)

Table 28. North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2019-2024) & (K Units)

Table 32. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2025-2030) & (K Units)

Table 33. Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2019-2024) & (K Units)

Table 47. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2025-2030) & (K Units)

Table 48. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2019-2024)

Table 51. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2025-2030)

Table 52. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2019-2024)

Table 53. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2025-2030)

Table 54. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2019-2024)

Table 57. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2025-2030)

Table 58. Global Postmenopausal Vaginal Atrophy Drugs Price (US$/Unit) by Type (2019-2024)

Table 59. Global Postmenopausal Vaginal Atrophy Drugs Price (US$/Unit) by Type (2025-2030)

Table 60. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Application (2019-2024)

Table 61. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Application (2025-2030)

Table 62. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2019-2024)

Table 63. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2025-2030)

Table 64. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2019-2024)

Table 67. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2025-2030)

Table 68. Global Postmenopausal Vaginal Atrophy Drugs Price (US$/Unit) by Application (2019-2024)

Table 69. Global Postmenopausal Vaginal Atrophy Drugs Price (US$/Unit) by Application (2025-2030)

Table 70. Pfizer Inc Corporation Information

Table 71. Pfizer Inc Description and Business Overview

Table 72. Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Product

Table 74. Pfizer Inc Recent Developments/Updates

Table 75. Mylan NV Corporation Information

Table 76. Mylan NV Description and Business Overview

Table 77. Mylan NV Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Mylan NV Postmenopausal Vaginal Atrophy Drugs Product

Table 79. Mylan NV Recent Developments/Updates

Table 80. Novartis AG Corporation Information

Table 81. Novartis AG Description and Business Overview

Table 82. Novartis AG Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Novartis AG Postmenopausal Vaginal Atrophy Drugs Product

Table 84. Novartis AG Recent Developments/Updates

Table 85. Hikma Pharmaceuticals plc Corporation Information

Table 86. Hikma Pharmaceuticals plc Description and Business Overview

Table 87. Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Product

Table 89. Hikma Pharmaceuticals plc Recent Developments/Updates

Table 90. Aurobindo Pharma Corporation Information

Table 91. Aurobindo Pharma Description and Business Overview

Table 92. Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Product

Table 94. Aurobindo Pharma Recent Developments/Updates

Table 95. AbbVie Inc Corporation Information

Table 96. AbbVie Inc Description and Business Overview

Table 97. AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Product

Table 99. AbbVie Inc Recent Developments/Updates

Table 100. Melinta Therapeutics, Inc Corporation Information

Table 101. Melinta Therapeutics, Inc Description and Business Overview

Table 102. Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Product

Table 104. Melinta Therapeutics, Inc Recent Developments/Updates

Table 105. Bristol-Myers Squibb Company Corporation Information

Table 106. Bristol-Myers Squibb Company Description and Business Overview

Table 107. Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Product

Table 109. Bristol-Myers Squibb Company Recent Developments/Updates

Table 110. GSK plc Corporation Information

Table 111. GSK plc Description and Business Overview

Table 112. GSK plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. GSK plc Postmenopausal Vaginal Atrophy Drugs Product

Table 114. GSK plc Recent Developments/Updates

Table 115. Bayer AG Corporation Information

Table 116. Bayer AG Description and Business Overview

Table 117. Bayer AG Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. Bayer AG Postmenopausal Vaginal Atrophy Drugs Product

Table 119. Bayer AG Recent Developments/Updates

Table 120. Lupin Corporation Information

Table 121. Lupin Description and Business Overview

Table 122. Lupin Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 123. Lupin Postmenopausal Vaginal Atrophy Drugs Product

Table 124. Lupin Recent Developments/Updates

Table 125. Perrigo Company plc Corporation Information

Table 126. Perrigo Company plc Description and Business Overview

Table 127. Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 128. Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Product

Table 129. Perrigo Company plc Recent Developments/Updates

Table 130. Bionovo, Inc Corporation Information

Table 131. Bionovo, Inc Description and Business Overview

Table 132. Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 133. Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Product

Table 134. Bionovo, Inc Recent Developments/Updates

Table 135. TherapeuticsMD, Inc Corporation Information

Table 136. TherapeuticsMD, Inc Description and Business Overview

Table 137. TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 138. TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Product

Table 139. TherapeuticsMD, Inc Recent Developments/Updates

Table 140. Endoceutics, Inc Corporation Information

Table 141. Endoceutics, Inc Description and Business Overview

Table 142. Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 143. Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Product

Table 144. Endoceutics, Inc Recent Developments/Updates

Table 145. Key Raw Materials Lists

Table 146. Raw Materials Key Suppliers Lists

Table 147. Postmenopausal Vaginal Atrophy Drugs Distributors List

Table 148. Postmenopausal Vaginal Atrophy Drugs Customers List

Table 149. Postmenopausal Vaginal Atrophy Drugs Market Trends

Table 150. Postmenopausal Vaginal Atrophy Drugs Market Drivers

Table 151. Postmenopausal Vaginal Atrophy Drugs Market Challenges

Table 152. Postmenopausal Vaginal Atrophy Drugs Market Restraints

Table 153. Research Programs/Design for This Report

Table 154. Key Data Information from Secondary Sources

Table 155. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Postmenopausal Vaginal Atrophy Drugs

Figure 2. Global Postmenopausal Vaginal Atrophy Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Postmenopausal Vaginal Atrophy Drugs Market Share by Type in 2023 & 2030

Figure 4. Topical Estrogen Product Picture

Figure 5. Oral Estrogen Product Picture

Figure 6. Other Product Picture

Figure 7. Global Postmenopausal Vaginal Atrophy Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 8. Global Postmenopausal Vaginal Atrophy Drugs Market Share by Application in 2023 & 2030

Figure 9. Online Pharmacy

Figure 10. Hospital Pharmacy

Figure 11. Global Postmenopausal Vaginal Atrophy Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 12. Global Postmenopausal Vaginal Atrophy Drugs Market Size (2019-2030) & (US$ Million)

Figure 13. Global Postmenopausal Vaginal Atrophy Drugs Sales (2019-2030) & (K Units)

Figure 14. Global Postmenopausal Vaginal Atrophy Drugs Average Price (US$/Unit) & (2019-2030)

Figure 15. Postmenopausal Vaginal Atrophy Drugs Report Years Considered

Figure 16. Postmenopausal Vaginal Atrophy Drugs Sales Share by Manufacturers in 2023

Figure 17. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers in 2023

Figure 18. The Global 5 and 10 Largest Postmenopausal Vaginal Atrophy Drugs Players: Market Share by Revenue in 2023

Figure 19. Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 20. Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 21. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2019-2030)

Figure 22. North America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2019-2030)

Figure 23. United States Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 24. Canada Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 25. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2019-2030)

Figure 26. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2019-2030)

Figure 27. Germany Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 28. France Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. U.K. Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. Italy Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Russia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2019-2030)

Figure 33. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2019-2030)

Figure 34. China Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. Japan Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. South Korea Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. India Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. Australia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. China Taiwan Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2019-2030)

Figure 42. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2019-2030)

Figure 43. Mexico Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Brazil Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Argentina Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2019-2030)

Figure 47. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2019-2030)

Figure 48. Turkey Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. UAE Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. Global Sales Market Share of Postmenopausal Vaginal Atrophy Drugs by Type (2019-2030)

Figure 52. Global Revenue Market Share of Postmenopausal Vaginal Atrophy Drugs by Type (2019-2030)

Figure 53. Global Postmenopausal Vaginal Atrophy Drugs Price (US$/Unit) by Type (2019-2030)

Figure 54. Global Sales Market Share of Postmenopausal Vaginal Atrophy Drugs by Application (2019-2030)

Figure 55. Global Revenue Market Share of Postmenopausal Vaginal Atrophy Drugs by Application (2019-2030)

Figure 56. Global Postmenopausal Vaginal Atrophy Drugs Price (US$/Unit) by Application (2019-2030)

Figure 57. Postmenopausal Vaginal Atrophy Drugs Value Chain

Figure 58. Postmenopausal Vaginal Atrophy Drugs Production Process

Figure 59. Channels of Distribution (Direct Vs Distribution)

Figure 60. Distributors Profiles

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions